Multiple sclerosis and nephrolithiasis: a matched‐case comparative study

Ganesan, Vishnu; Chen, Wen Min; Jain, Rajat; De, Shubha; Monga, Manoj

doi:10.1111/bju.13820

Cited by 13 publications

(13 citation statements)

References 26 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…This patient had no risk factors for UA urolithiasis (eg, diabetes, metabolic syndrome, hyperuricemia), no unbalanced diet, no urinary tract infection, no personal or family history of urinary stones, no structural anomalies of the urinary tract, and no urinary tract obstruction. In MS patients, the increased prevalence of struvite and calcium phosphate upper tract stones is thought to be driven by infected urine secondary to neurogenic bladder [2]. In this patient, the nature of the stones and the absence of a neurogenic bladder did not support MS‐related urolithiasis.…”

Section: Discussionmentioning

confidence: 89%

Teriflunomide‐associated urolithiasis: a new adverse reaction explained by its uricosuric effect

Largeau

Bera

Vannier

et al. 2021

Fundamemntal Clinical Pharma

View full text Add to dashboard Cite

In clinical trials, few investigations have been conducted to determine the mechanism involved in teriflunomide‐associated kidney stone formation. We report the first case of recurrent teriflunomide‐induced uric acid urolithiasis. A 55‐year‐old man with relapsing‐remitting multiple sclerosis experienced three occurrences of urolithiasis several months after the initiation of teriflunomide. While serum uric acid remained stable at 280 mmol/L, 24‐h urine uric acid was increased to 2195 mmol/24 h. For the third episode, computed tomography showed three bladder stones and one stone in the right calyceal group. Endovesical lithotripsy was used to extract four orange‐colored stones of more than 20 mm. Stone analysis exhibited morphology subtype IIIb with 100% of anhydrous uric acid. Given the disease control, teriflunomide was continued. After urinary alkalinization by potassium citrate, the patient remained asymptomatic at 18 months follow‐up. An inhibitory effect of dihydroorotate and/or teriflunomide on urate tubular reabsorption could explain teriflunomide‐associated uric acid urolithiasis. This case in a patient without risk factors suggests that multiple sclerosis patients may be at greater risk of forming uric acid urinary stones when taking teriflunomide. Alkalinization of the urine may reduce the risk of recurrence, allowing further treatment with teriflunomide.

show abstract

Section: Discussionmentioning

confidence: 89%

Teriflunomide‐associated urolithiasis: a new adverse reaction explained by its uricosuric effect

Largeau

Bera

Vannier

et al. 2021

Fundamemntal Clinical Pharma

View full text Add to dashboard Cite

show abstract

“…[15,[18][19][20] However, 2 cases progressed to chronic kidney disease even after IFN β was discontinued. [15,19] Other renal pathologies included acute renal failure from nephrogenic lower urinary tract dysfunction, [10] and nephrolithiasis [1] found among MS patients.…”

Section: Resultsmentioning

confidence: 99%

“…[1] struvite stones are associated with the formation of staghorn calculi, and given the increased risk of UTI and bacteriuria in MS patients; [31] there is a possibility of an increased risk of struvite stones and formation of staghorn calculi in MS patients. [1]…”

Section: Discussionmentioning

confidence: 99%

“…Ganesan et al, 2017 [1] Patients at a large, urban academic tertiary care center and its satellite facilities/118 MS patients with stone disease. Out of these 118, 61 MS patients had a complete 24-h urinary stone panel analysis.…”

Section: Renal Disease Implicated Summarymentioning

confidence: 99%

“…Multiple sclerosis (MS) is a demyelinating inflammatory disease of the central nervous system, [1] it is one of the leading causes of progressive neurological disability in young adults [2] with an estimated prevalence of 85 per 100,000 in the United States and 100 per 100,000 in Europe. [3,4] It has historically been classified as an organ-specific T-cell mediated autoimmune disease.…”

Section: Introductionmentioning

confidence: 99%

See 2 more Smart Citations

Renal diseases associated with multiple sclerosis: A narrative review

Alugba¹,

Urhi²,

Olateju³

et al. 2022

Medicine

View full text Add to dashboard Cite

The mechanisms of renal pathology in multiple sclerosis (MS) can be related to the disease itself or its treatment. Although kidney disease can be associated with MS, not much has been reported in the literature; hence, our study aimed to describe the prevalence and types of renal diseases and discuss their prognosis in patients with MS. A literature search (2012-2022) was performed using the Scale for the Assessment of Narrative Review Articles. The databases searched included MEDLINE (PubMed) and EMBASE. Fourteen articles from these databases met the inclusion criteria. The inclusion criteria were as follows: publications with full-text access. Articles published in English. Original articles related to renal diseases in MS. The prevalence of renal diseases in MS from the articles obtained ranged from 0.74% to 2.49%. Interferon beta (IFN-β)-associated glomerulonephritis was common among the reviewed articles. Significant improvement and resolution of the pathology were observed after the discontinuation of the offending medication. Renal symptoms in 2 out of 4 cases with renal thrombotic microangiopathy (TMA) induced by interferon-beta progressed to chronic kidney disease, even after the drug was stopped. Other studied renal pathologies included nephrolithiasis secondary to urinary retention and urinary catheter use in patients with MS.

show abstract

Risk factors of bladder stones in neurogenic lower urinary tract dysfunction: A real‐world study

Möhr,

Fassbind,

Gahl

et al. 2024

BJUI Compass

View full text Add to dashboard Cite

ObjectiveThe objective of this study is to investigate the incidence and risk factors for stone formation and recurrence in patients with neurogenic lower urinary tract dysfunction (NLUTD) in a real‐world cohort.Materials and methodsA retrospective cohort study was conducted on all patients with NLUTD who underwent bladder stone treatment between 2010 and 2022. Univariate and multivariate Cox models were used to identify the potential risk factors for stone recurrence.ResultsAmong 114 patients included in the study, 30% experienced stone recurrence. The most common stone components were carbonate apatite phosphate and magnesium ammonium phosphate. The overall recurrence rate was 14 cases per 100 patient years. Neurogenic detrusor overactivity had the highest recurrence rate. Risk factors for stone recurrence in the multivariate analysis were intermittent and suprapubic catheterization, and recurrent urinary tract infection (rUTI).ConclusionsPatients experienced multiple bladder stone recurrences. Close monitoring of bladder pressure and UTI with restrictive catheter application may reduce the risk of stone recurrence.

show abstract

Multiple sclerosis and nephrolithiasis: a matched‐case comparative study

Cited by 13 publications

References 26 publications

Teriflunomide‐associated urolithiasis: a new adverse reaction explained by its uricosuric effect

Teriflunomide‐associated urolithiasis: a new adverse reaction explained by its uricosuric effect

Renal diseases associated with multiple sclerosis: A narrative review

Risk factors of bladder stones in neurogenic lower urinary tract dysfunction: A real‐world study

Contact Info

Product

Resources

About